Literature DB >> 1650212

The H+, K(+)-ATPase inhibitor pantoprazole (BY1023/SK&F96022) interacts less with cytochrome P450 than omeprazole and lansoprazole.

W A Simon1, C Büdingen, S Fahr, B Kinder, M Koske.   

Abstract

The gastric acid antisecretory compound omeprazole (5-methoxy-2-((4-methoxy- 3,5-dimethyl-2-pyridinylmethyl)-sulphinyl)-1H-benzimidazole), a member of the new class of H+, K(+)-ATPase inhibitors, is known to interact with the metabolism of other drugs in vitro and in vivo. In this study, two other substituted benzimidazoles, pantoprazole (5-difluoromethoxy-2-((3,4-di-methoxy-2-pyridinylmethyl)-s ulp hinyl)-1H- benzimidazole) and lansoprazole (2-((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinylmethyl)- sulphinyl)-1H-benzimidazole) are compared for their ability to inhibit cytochrome P450 dependent biotransformation in vitro with regard to three representative reactions: O-dealkylation of 7-ethoxycoumarin (EC), N-demethylation of ethylmorphine (EM) and hydroxylation of lonazolac (Lona). These reactions can be seen in microsomes from phenobarbital pretreated rats representing the cytochrome P450IIB1 subfamily. As shown in presence of known inhibitors of cytochrome P450, e.g. SK&F 525A, metyrapone, chlorpromazine and nitrendipine, different enzymes seem to be responsible for these three indicator reactions of the cytochrome P450IIB1 complex. These reactions are inhibited to a different extent by the three H+, K(+)-ATPase inhibitors. Pantoprazole shows the lowest inhibitory activity versus the three reactions (Ki, mumol/L): EC, 138; EM, 104; Lona, 128. A greater effect is observed with omeprazole: EC, 38; EM, 68; Lona, 20. Lansoprazole exceeds omeprazole in inhibiting the three cytochrome P450 dependent enzymes: EC, 17; EM, 34; Lona, 8. In microsomes from untreated rats with the predominant cytochrome P450IIA1 subfamily as well as in microsomes from isopropanol treated rats (induction of cytochrome P450IIE1) which catalyse only lonazolac hydroxylation to a detectable amount, the latter reaction was inhibited by pantoprazole with a somewhat lower Ki of 77 whereas the values for omeprazole and lansoprazole remained unchanged in comparison to those found in microsomes from phenobarbital pretreated rats. The biotransformation rate of the substituted benzimidazoles themselves in microsomes from control and induced rats is lowest for pantoprazole followed by lansoprazole and omeprazole.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1650212     DOI: 10.1016/0006-2952(91)90722-h

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  7 in total

1.  Interaction risk with proton pump inhibitors in general practice: significant disagreement between different drug-related information sources.

Authors:  Gianluca Trifirò; Salvatore Corrao; Marianna Alacqua; Salvatore Moretti; Michele Tari; Achille P Caputi; Vincenzo Arcoraci
Journal:  Br J Clin Pharmacol       Date:  2006-07-06       Impact factor: 4.335

Review 2.  Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders.

Authors:  A Fitton; L Wiseman
Journal:  Drugs       Date:  1996-03       Impact factor: 9.546

3.  Effects of lansoprazole on pharmacokinetics and metabolism of theophylline.

Authors:  T Kokufu; N Ihara; N Sugioka; H Koyama; T Ohta; S Mori; K Nakajima
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

4.  Omeprazole inhibits colorectal carcinogenesis induced by azoxymethane in rats.

Authors:  I D Penman; E el-Omar; J R McGregor; K J Hillan; P J O'Dwyer; K E McColl
Journal:  Gut       Date:  1993-11       Impact factor: 23.059

Review 5.  Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders.

Authors:  C M Spencer; D Faulds
Journal:  Drugs       Date:  1994-09       Impact factor: 9.546

Review 6.  Proton pump inhibitory therapy: then and now.

Authors:  W Schepp
Journal:  Yale J Biol Med       Date:  1996 Mar-Apr

7.  Pharmacokinetics and pharmacodynamics of the proton pump inhibitors.

Authors:  Jai Moo Shin; Nayoung Kim
Journal:  J Neurogastroenterol Motil       Date:  2013-01-08       Impact factor: 4.924

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.